Lynparza

Chemical Nameolaparib
Dosage FormTablets (oral; 150 mg, 100 mg)
Drug ClassInhibitors
SystemFemale reproductive
CompanyAstraZeneca
Approval Year2014

Indication

  • For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum based chemotherapy.
  • For the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.
Last updated on 4/19/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Lynparza (olaparib) Prescribing Information2014AstraZeneca Pharmaceuticals, Wilmington, DE